RxDoctor Payments DataLook up a doctor →

Mohanjit Brar, MD

Interventional Cardiology · Edgewood, KYNPI 1386665040

Payments from drug & device makers

$215,782in general payments, 2019–2025

Across 544 payments — averaging $396.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cathworks, Inc.$95K
  • Johnson & Johnson$47K
  • Medtronic$28K
  • Magenta Medical Inc$23K
  • Abbott$6K
  • Abiomed$3K
  • plus $12K from 32 others

What the payments were for

  • Consulting fees$4,0005%
  • Speaking & faculty fees$44,49559%
  • Travel & lodging$7,0289%
  • Food & beverage$20,22727%
  • Education$1030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$215,782 in reported general payments places this provider in the 90th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$165,467
Medicare patients
936
Services billed
1,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban289$325,714
EliquisApixaban273$267,882
Repatha SureclickEvolocumab78$58,725
EntrestoSacubitril/Valsartan30$40,839
FarxigaDapagliflozin Propanediol27$35,770
Praluent PenAlirocumab25$24,805
BrilintaTicagrelor16$14,085
VascepaIcosapent Ethyl23$13,916
Metoprolol Succinate517$6,770
Ranolazine ErRanolazine75$6,244
Bisoprolol Fumarate159$3,111
Torsemide180$2,710
Atorvastatin Calcium296$2,412
Amiodarone Hcl42$2,117
Losartan Potassium207$1,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$47,317$325,714289 claims
PfizerEliquis$174$267,882273 claims
AstraZenecaFarxiga, Brilinta$243$49,85643 claims
NovartisEntresto$334$40,83930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 129 interventional cardiology providers in Kentucky.

Other interventional cardiology in Edgewood

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →